Table 2 Hemodynamic measurements, elastography, laboratory findings, chemotherapy, SOS, and complications
Patient | HVPG | Elastography | Platelets | PT (%) | Chemotherapy (cycles) | OBC | SOS | Complications |
|---|---|---|---|---|---|---|---|---|
1 | 4.50 | 6.80 | 336,000 | 100 | FOLFOX [6] | Yes | Yes | 0 |
2 | 6.50 | N/A | 157,000 | 100 | FOLFOX [8] | Yes | Yes | I |
3 | 2.00 | N/A | 135,000 | 76 | Capecitabine [2] | – | – | 0 |
4 | 4.00 | N/A | 105,000 | 98 | FOLFOX [9] | – | Yes | I |
5 | 7.00 | 7.90 | 150,000 | 95 | FOLFOXIRI [8] | Yes | Yes | IIIA |
6 | 6.00 | 8.40 | 136,000 | 89 | FOLFOX [6] | Yes | Yes | IIIA |
7 | 2.00 | N/A | 196,000 | 99 | FOLFOX + FOLFIRI [12] | – | – | I |
8 | 2.50 | 3.80 | 192,000 | 100 | FOLFOX [4] | Yes | – | I |
9 | 2.50 | 4.70 | 199,000 | 100 | Capecitabine [1] | – | – | 0 |
10 | 1.50 | N/A | 197,000 | 100 | FOLFOX + bevacizumab [7] | – | – | I |
11 | 5.00 | N/A | 191,000 | 100 | FOLFOX [4] | Yes | Yes | IIIB |
12 | 2.50 | 5.20 | 274,000 | 100 | Capecitabine [6] | – | – | 0 |
13 | 4.00 | 4.40 | 157,000 | 100 | FOLFOX [5] | Yes | Yes | IIB |
14 | 4.00 | 6.10 | 135,000 | 100 | FOLFOX [3] | – | – | I |
15 | 4.00 | 7.60 | 283,000 | 100 | FOLFOX [6] | Yes | – | I |
16 | 2.50 | 3.60 | 215,000 | 92 | FOLFIRI + cetuximab [6] | – | – | I |
17 | 6.00 | 4.50 | 291,000 | 78 | TOMOX [6] | Yes | Yes | IIIA |
18 | 2.00 | 5.20 | 157,000 | 100 | FOLFOX + TOMOX + panitumumab [8] | – | – | 0 |
19 | 4.5 | 4.00 | 331,000 | 100 | FOLFOX [5] | Yes | Yes | 0 |
20 | 3 | 3.50 | 335,000 | 62.50 | XELOX [5] | Yes | – | IIIB |